INT102064

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.20
First Reported 2002
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 3
Total Number 4
Disease Relevance 0.86
Pain Relevance 1.55

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (Sstr5) plasma membrane (Sstr5) cytoplasm (Sstr5)
signal transducer activity (Sstr5)
Anatomy Link Frequency
superior 2
Sstr5 (Mus musculus)
Pain Link Frequency Relevance Heat
Somatostatin 57 99.78 Very High Very High Very High
dexamethasone 4 97.28 Very High Very High Very High
agonist 22 94.76 High High
Neuropeptide 2 61.04 Quite High
antagonist 13 56.40 Quite High
Dopamine 4 56.36 Quite High
Potency 1 39.28 Quite Low
Pain 3 25.00 Low Low
Glutamate 1 25.00 Low Low
imagery 10 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Adenoma 12 96.32 Very High Very High Very High
Acth-secreting Pituitary Adenoma 14 92.80 High High
Acromegaly 40 82.56 Quite High
Pituitary Acth Hypersecretion 6 50.00 Quite Low
Pituitary Cancer 16 45.16 Quite Low
Nelson Syndrome 6 45.04 Quite Low
Diabetes Mellitus 20 34.36 Quite Low
Cancer 36 25.00 Low Low
Pain 2 25.00 Low Low
Convulsion 1 25.00 Low Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In fact, octreotide (that binds preferentially sst2 but only modestly sst5), but not pasireotide (a universal ligand with high binding affinity for sst1, sst2, sst3, and sst5), lost most of its ACTH-inhibiting potential with glucocorticoid pretreatment53 or in patients with CD in vivo.54 Two studies55,56 investigated the effects of SS analogs in human corticotroph adenoma tissues; a superior ACTH inhibition by pasireotide as compared with octreotide55 and a dissociation in some adenomas between the antisecretory and antiproliferative effects of pasireotide56 were reported similar to what is observed in acromegaly.57,58

Efficacy in clinical studies

sst5 Binding (binds) of in superior associated with adenoma, acromegaly, acth-secreting pituitary adenoma and somatostatin
1) Confidence 0.20 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2963160 Disease Relevance 0.31 Pain Relevance 0.61
In fact, octreotide (that binds preferentially sst2 but only modestly sst5), but not pasireotide (a universal ligand with high binding affinity for sst1, sst2, sst3, and sst5), lost most of its ACTH-inhibiting potential with glucocorticoid pretreatment53 or in patients with CD in vivo.54 Two studies55,56 investigated the effects of SS analogs in human corticotroph adenoma tissues; a superior ACTH inhibition by pasireotide as compared with octreotide55 and a dissociation in some adenomas between the antisecretory and antiproliferative effects of pasireotide56 were reported similar to what is observed in acromegaly.57,58

Efficacy in clinical studies

sst5 Neg (not) Binding (ligand) of in superior associated with adenoma, acromegaly, acth-secreting pituitary adenoma and somatostatin
2) Confidence 0.15 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2963160 Disease Relevance 0.37 Pain Relevance 0.62
In contrast, [125I]Tyr3octreotide, [125I]BIM23027, [125I]MK678 or [125I]D-Trp8SRIF14 label predominantly SRIF1 sites, especially sst2 and possibly sst5 receptors.
sst5 Binding (receptors) of
3) Confidence 0.07 Published 2002 Journal J. Mol. Neurosci. Section Abstract Doc Link 11931345 Disease Relevance 0 Pain Relevance 0.12
Five subtypes (sst1–5) have been described, and the currently available somatostatin analogues bind with high affinity to sst2 and sst5.
sst5 Binding (bind) of associated with somatostatin
4) Confidence 0.05 Published 2008 Journal Clinical Endocrinology Section Body Doc Link PMC2610402 Disease Relevance 0.17 Pain Relevance 0.19

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox